魚嶋 晴紀HARUKI UOJIMA

Ⅰ）原著：

1. Different clinical courses in two cases of ruptured liver abscesses depending on the presence or absence of gas-producing pathogens. Uojima H, Tokoro S, Masuda S, Tomishima K, Sasaki A, Kimbara T, Kako M. Nihon Shokakibyo Gakkai Zasshi. 2013 Dec;110(12):2136-41.PMID: 24305103 Japanese.

2. A case of arteriovenous malformation of the pancreas treated with n-butyl-2-cyanoacrylate transcatheter arterial embolization. Uojima H, Tsukiyama T, Ichida C, Tsuchiya T, Itoi T.Nihon Shokakibyo Gakkai Zasshi. 2014 Nov;111(11):2174-80.PMID: 25373379 Review. Japanese.

3. Endoscopic ultrasound-guided drainage of an amoebic liver abscess extending into the hepatic subcapsular space.Koizumi K, Masuda S, Uojima H, Ichita C, Tokoro S, Sasaki A, Egashira H, Kimbara T, Kako M. Clin J Gastroenterol. 2015 Aug;8(4):232-5. doi: 10.1007/s12328-015-0585-8. Epub 2015 Jul 24.PMID: 26204883

4. Condyloma acuminatum of the anal canal, treated with endoscopic submucosal dissection.Sasaki A, Nakajima T, Egashira H, Takeda K, Tokoro S, Ichita C, Masuda S, Uojima H, Koizumi K, Kinbara T, Sakamoto T, Saito Y, Kako M.World J Gastroenterol. 2016 Feb 28;22(8):2636-41. doi: 10.3748/wjg.v22.i8.2636.PMID: 26937152 Free PMC article.

5. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites.Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M, Tokoro S, Masuda S, Takizawa S, Sasaki A, Koizumi K, Egashira H, Kako M.Hepatol Res. 2017 Mar;47(3):E14-E21. doi: 10.1111/hepr.12716. Epub 2016 May 19.PMID: 27059410

6. Superparamagnetic iron oxide-enhanced magnetic resonance imaging is useful in predicting malignant potential of vascular transformation of hypointense hypovascular nodules on gadoxetic acid-enhanced magnetic resonance imaging.Tanaka Y, Nakazawa T, Inoue T, Yamane K, Kubota K, Uojima H, Takada J, Okuwaki Y, Hidaka H, Shibuya A, Kokubu S, Matsunaga K, Koizumi W.Hepatol Res. 2017 Oct;47(11):1118-1126. doi: 10.1111/hepr.12850. Epub 2017 Feb 21.PMID: 27943555

7. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma.Kubota K, Hidaka H, Nakazawa T, Okuwaki Y, Yamane K, Inoue T, Uojima H, Takada J, Tanaka Y, Shibuya A, Fujii K, Woodhams R, Matsunaga K, Kokubu S, Koizumi W.Hepatol Res. 2018 Feb;48(3):E98-E106. doi: 10.1111/hepr.12933. Epub 2017 Jul 30.PMID: 28656607

8. Response criteria of tolvaptan for the treatment of hepatic edema.Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H, Uto H, Sakaida I, Izumi N, Okita K, Koike K.J Gastroenterol. 2018 Feb;53(2):258-268. doi: 10.1007/s00535-017-1366-6. Epub 2017 Jun 29.PMID: 28664229

9. Platypnea-orthodeoxia Syndrome Induced by an Infected Giant Hepatic Cyst.Hyun Sung J, Uojima H, Branch J, Miyazono S, Kitagawa I, Kako M, Kobayashi S. Intern Med. 2017;56(15):2019-2024. doi: 10.2169/internalmedicine.56.8004. Epub 2017 Aug 1.PMID: 28768974 Free PMC article.

10. Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis.Uojima H, Sakurai S, Hidaka H, Kinbara T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M, Kobayashi S.Eur J Gastroenterol Hepatol. 2017 Dec;29(12):1402-1407. doi:10.1097/MEG.0000000000000968. PMID: 28984678

11. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W.Intern Med. 2018 Apr 1;57(7):951-956. doi: 10.2169/internalmedicine.9671-17. Epub 2017 Dec 8.PMID: 29225269 Free PMC article.

12. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M.World J Gastroenterol. 2017 Dec 7;23(45):8062-8072. doi: 10.3748/wjg.v23.i45.8062.PMID: 29259382 Free PMC article. Clinical Trial.

13. Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis.Uojima H, Hidaka H, Tanaka Y, Inoue T, Onoue M, Wada N, Kubota K, Nakazawa T, Shibuya A, Fujikawa T, Nakayama T, Yamanoue H, Sung JH, Kako M, Koizumi W.J Gastroenterol Hepatol. 2018 Nov;33(11):1889-1896. doi: 10.1111/jgh.14277. Epub 2018 May 29.PMID: 29737582

14. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T.J Gastroenterol. 2018 Dec;53(12):1276-1284. doi: 10.1007/s00535-018-1473-z. Epub 2018 May 8.PMID: 29740665

15. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K.J Gastroenterol Hepatol. 2019 Feb;34(2):364-369. doi: 10.1111/jgh.14447. Epub 2018 Sep 14.PMID: 30144366

16. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K.Hepatol Res. 2019 Apr;49(4):369-376. doi: 10.1111/hepr.13292. Epub 2019 Jan 2.PMID: 30485638

17. Relationship between response to lusutrombopag and splenic volume.Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W.World J Gastroenterol. 2018 Dec 14;24(46):5271-5279. doi: 10.3748/wjg.v24.i46.5271.PMID: 30581275 Free PMC article.

18. Risk factors for loss of skeletal muscle mass in patients with cirrhosis.Sung JH, Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, Nakazawa T, Shibuya A, Fujikawa T, Yamanoue H, Kako M, Koizumi W.Hepatol Res. 2019 May;49(5):550-558. doi: 10.1111/hepr.13308. Epub 2019 Feb 1.PMID: 30623996

19. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K.Aliment Pharmacol Ther. 2019 May;49(9):1230-1241. doi: 10.1111/apt.15218. Epub 2019 Mar 14.PMID: 30873651 Clinical Trial.

20. A suspected case of Clostridium perfringens sepsis with intravascular hemolysis after transhepatic arterial chemoembolization: a case report.Uojima H, Onoue M, Hidaka H, Wada N, Tanaka Y, Inoue T, Kubota K, Nakazawa T, Shibuya A, Koizumi W.J Med Case Rep. 2019 Apr 27;13(1):125. doi: 10.1186/s13256-019-2023-x.PMID: 31027514 Free PMC article.

21. [Endoscopic treatments for portal hypertension].Hidaka H, Uojima H, Kokubu S.Nihon Shokakibyo Gakkai Zasshi. 2019;116(5):395-403. doi: 10.11405/nisshoshi.116.395.PMID: 31080219 Japanese. No abstract available.

22. Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients.Uojima H, Kobayashi S, Hidaka H, Kinbara T, Fujikawa T, Nakayama T, Yamanoue H, Kanemaru T, Hashimotoh T, Hyun Sung J, Kako M, Koizumi W.Ann Hepatol. 2019 Jan-Feb;18(1):109-115. doi: 10.5604/01.3001.0012.7868.PMID: 31113578 Free article. Clinical Trial.

23. Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T.Open Forum Infect Dis. 2019 Apr 15;6(5):ofz185. doi: 10.1093/ofid/ofz185. eCollection 2019 May.PMID: 31123693 Free PMC article.

24. Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, Nakazawa T, Shibuya A, Sung JH, Kako M, Koizumi W.Dig Dis. 2020;38(1):38-45. doi:10.1159/000501267. Epub 2019 Jun 19.PMID: 31216537 Clinical Trial.

25. Hepatic methotrexate-associated lymphoproliferative disorders identified by multiple liver tumors: a case report and review of the literature.Ono R, Kumagae T, Uojima H, Teshima S, Kudo M, Kitagawa I, Yoshizawa M.J Med Case Rep. 2019 Jun 27;13(1):196. doi: 10.1186/s13256-019-2135-3.PMID: 31242930 Free PMC article. Review.

26. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T.J Viral Hepat. 2019 Nov;26(11):1266-1275. doi: 10.1111/jvh.13170. Epub 2019 Aug 9.PMID: 31278795

27. Ischemic pancreatitis with infected walled-off necrosis with a colonic fistula after cardiopulmonary bypass successfully treated by endoscopic ultrasound-guided drainage.Masuda S, Koizumi K, Uojima H, Tazawa T, Tasaki J, Ichita C, Nishino T, Kimura K, Sasaki A, Egashira H, Kako M.Clin J Gastroenterol. 2020 Feb;13(1):127-133. doi: 10.1007/s12328-019-01019-0. Epub 2019 Jul 20.PMID: 31327132

28. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T.J Gastroenterol Hepatol. 2020 May;35(5):855-861. doi: 10.1111/jgh.14874. Epub 2019 Nov 19　PMID: 31609495 Clinical Trial.

29. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.Atsukawa M, Tsubota A, Takaguchi K, Toyoda H, Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K.J Gastroenterol Hepatol. 2020 Jul;35(7):1229-1237. doi: 10.1111/jgh.14965. Epub 2020 Jan 14.PMID: 31881554

30. Usefulness of autotaxin for the complications of liver cirrhosis.Shao X, Uojima H, Setsu T, Okubo T, Atsukawa M, Furuichi Y, Arase Y, Hidaka H, Tanaka Y, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Terai S, Koizumi W.World J Gastroenterol. 2020 Jan 7;26(1):97-108. doi: 10.3748/wjg.v26.i1.97.PMID: 31933517 Free PMC article.

31. Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T.J Gastroenterol Hepatol. 2020 Aug;35(8):1420-1425. doi: 10.1111/jgh.14982. Epub 2020 Jan 31.PMID: 31950525

32. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S.Cancers (Basel). 2020 Jan 6;12(2):293.doi:10.3390/cancers12020293.

      PMID: 31991869 Free PMC article.

33. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group.Hepatol Int. 2020 Mar;14(2):225-238. doi: 10.1007/s12072-020-10019-z. Epub 2020 Mar 3.PMID: 32128704

34. Pancreatic pseudocyst-portal vein fistula: a case treated with EUS-guided cyst-drainage and a review of the literature.Masuda S, Koizumi K, Uojima H, Tazawa T, Kimura K, Nishino T, Tasaki J, Ichita C, Sasaki A, Egashira H, Kako M.Clin J Gastroenterol. 2020 Aug;13(4):597-606. doi: 10.1007/s12328-020-01105-8. Epub 2020 Mar 25.PMID: 32215857 Review.

35. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib.Uojima H, Chuma M, Tanaka Y, Hidaka H, Nakazawa T, Iwabuchi S, Kobayashi S, Hattori N, Ogushi K, Morimoto M, Kagawa T, Tanaka K, Kako M, Koizumi W.Liver Cancer. 2020 Apr;9(2):193-206. doi: 10.1159/000504604. Epub 2019 Dec 6.PMID: 32399433 Free PMC article.

36. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study.Hidaka H, Uojima H, Nakazawa T, Shao X, Hara Y, Iwasaki S, Wada N, Kubota K, Tanaka Y, Shibuya A, Kanoh Y, Kokubu S, Koizumi W.Hepatol Res. 2020 Sep;50(9):1083-1090. doi: 10.1111/hepr.13531. Epub 2020 Jul 27.PMID: 32515895

37. Undifferentiated Embryonal Sarcoma of the Liver Identified after the Initial Diagnosis of a Hepatic Cyst.Manabe Y, Uojima H, Hidaka H, Shao X, Iwasaki S, Wada N, Kubota K, Tanaka Y, Nakazawa T, Shibuya A, Ichinoe M, Kumamoto Y, Kaizu T, Koizumi W.Intern Med. 2020 Oct 1;59(19):2375-2382. doi: 10.2169/internalmedicine.4853-20. Epub2020Jun 30.PMID: 32611966 Free PMC article.

38. Clinicopathological Features of Autoimmune Hepatitis with IgG4-Positive Plasma Cell Infiltration.Arase Y, Matsumoto K, Anzai K, Tsuruya K, Sugiyama S, Yoshihara S, Hirose S, Uojima H, Hidaka H, Nakazawa T, Deguchi R, Kojima S, Takashimizu S, Shiraishi K, Shirai T, Kagawa T.Dig Dis. 2021;39(3):225-233. doi: 10.1159/000510562. Epub 2020 Jul 30.PMID: 32731217 Free PMC article.

39. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.Wada N, Uojima H, Satoh T, Okina S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W.Dig Dis. 2021;39(3):234-242. doi: 10.1159/000510692. Epub 2020 Aug 6.PMID: 32759604 Free PMC article. Clinical Trial.

40. Long-term observation in patients with esophageal varices after endoscopic variceal ligation accompanied with 24-hour pH monitoring.Hidaka H, Tanabe S, Uojima H, Shao X, Iwasaki S, Wada N, Kubota K, Tanaka Y, Nakazawa T, Shibuya A, Kokubu S, Koizumi W.Hepatol Res. 2020 Nov;50(11):1255-1263. doi: 10.1111/hepr.13562. Epub 2020 Sep 10.PMID: 32838474

41. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asai A, Asano T, Ogawa C, Abe H, Hotta N, Shima T, Iio E, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Hidaka I, Moriya A, Tsuji K, Akahane T, Yamashita N, Okubo T, Arai T, Morita K, Kawata K, Tanaka Y, Okanoue T, Maeda S, Kumada T, Iwakiri K; KTK49 Liver Study Group.Infect Dis Ther. 2020 Dec;9(4):851-866. doi: 10.1007/s40121-020-00329-y. Epub 2020 Sep 8.PMID: 32897520 Free PMC article.

42. Secondary Minimal Change Disease Due to Pancreatic Cancer Improved by Chemotherapy.Masuda S, Koizumi K, Moriya H, Nishino T, Uojima H, Tazawa T, Kimura K, Tasaki J, Ichita C, Sasaki A, Kako M, Hidaka S, Kudo M.Intern Med. 2021 Jan 15;60(2):251-257. doi: 10.2169/internalmedicine.5499-20. Epub 2020 Sep 19.PMID: 32963158 Free PMC article.

43. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K.Sci Rep. 2020 Oct 13;10(1):17054. doi: 10.1038/s41598-020-73930-3.PMID: 33051476 Free PMC article.

44. Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S.Clin Exp Gastroenterol. 2020 Oct 1;13:385-396. doi: 10.2147/CEG.S256691. eCollection 2020.PMID: 33061517 Free PMC article.

45. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis.Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S.Hepatol Res. 2021 Feb;51(2):201-215. doi: 10.1111/hepr.13592. Epub 2021 Jan 5.PMID: 33270323

46. Impact of non-pharmaceutical interventions for the COVID-19 pandemic on emergency department patient trends in Japan: a retrospective analysis.Sekine I, Uojima H, Koyama H, Kamio T, Sato M, Yamamoto T, Fukaguchi K, Fukui H, Yamagami H.Acute Med Surg. 2020 Nov 28;7(1):e603. doi: 10.1002/ams2.603. eCollection 2020 Jan-Dec.PMID: 33282316 Free PMC article.

47. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B.Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Akito N, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita AN, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K.JGH Open. 2020 Nov 2;5(1):34-40. doi: 10.1002/jgh3.12443. eCollection 2021 Jan.PMID: 33490611 Free PMC article.

48. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, Liu J, Quek SXZ, Ishikawa T, Arai T, Yokohama K, Chuma M, Takaguchi K, Uojima H, Senoo T, Dang H, Maeda M, Hoang J, Le RH, Yasuda S, Thin KN, Tran S, Chien N, Henry L, Asai A, Fukunishi S, Cheung R, Lim SG, Trinh HN, Nguyen MH.Hepatology. 2021 Aug;74(2):656-666. doi: 10.1002/hep.31793. Epub 2021 May 22.PMID: 33706421

49. Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K.Sci Rep. 2021 Apr 14;11(1):8550. doi: 10.1038/s41598-021-86457-y.PMID: 33854083 Free PMC article. No abstract available.

50. Cartilage-hair Hypoplasia Complicated with Liver Cirrhosis Due to Chronic Intrahepatic Cholestasis.Kogami T, Uojima H, Ebato T, Bando Y, Hoshino A, Saegusa M, Ohbu M, Iwasaki S, Wada N, Kubota K, Tanaka Y, Hidaka H, Nakazawa T, Shibuya A, Koizumi W.Intern Med. 2021 Nov 1;60(21):3427-3433. doi: 10.2169/internalmedicine.7483-21. Epub 2021 May 7.PMID: 33967143 Free PMC article.

51. A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma.Iwasaki S, Hidaka H, Uojima H, Hashimura M, Nabeta T, Sanoyama I, Wada N, Kubota K, Nakazawa T, Shibuya A, Koizumi W.Clin J Gastroenterol. 2021 Aug;14(4):1233-1239. doi: 10.1007/s12328-021-01442-2. Epub 2021 May 23.PMID: 34024039

52. Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology.Kikuchi N, Uojima H, Hidaka H, Iwasaki S, Wada N, Kubota K, Nakazawa T, Shibuya A, Fujikawa T, Kako M, Sato T, Koizumi W.Hepatol Res. 2021 Sep;51(9):968-978. doi:10.1111/hepr.13698. Epub 2021 Jul 31.PMID: 34269502

53. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response.Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J.Hepatol Commun. 2021 May 5;5(7):1290-1299. doi: 10.1002/hep4.1716. eCollection 2021 Jul.PMID: 34278176 Free PMC article.

54. A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.Kawaratani H, Sawai H, Onishi M, Kogiso T, Shimada N, Uojima H, Nakajima T, Matsumoto N, Ikejima K, Ishikawa T, Terai S, Motoyama H, Komori A, Hirashima N, Saito S, Eguchi Y, Nojima M, Kawai Y, Tateyama M, Yoshiji H, Tanaka Y.Liver Int. 2021 Dec;41(12):2944-2953. doi: 10.1111/liv.15022. Epub 2021 Aug 8.PMID: 34309184

55. Additional L-Carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin.Kubota K, Uojima H, Shao X, Iwasaki S, Hidaka H, Wada N, Nakazawa T, Shibuya A, Kako M, Koizumi W.Dig Dis. 2022;40(3):313-321. doi: 10.1159/000518067. Epub 2021 Jun 28.PMID: 34348263 Free article. Clinical Trial.

56. Effect of Antibiotic Resistance of Pathogens on Initial Antibiotic Therapy for Patients With Cholangitis.Masuda S, Koizumi K, Uojima H, Kimura K, Nishino T, Tasaki J, Ichita C, Sasaki A.Cureus. 2021 Oct 3;13(10):e18449. doi: 10.7759/cureus.18449. eCollection 2021 Oct.PMID: 34650837 Free PMC article.

57. Direct oral anticoagulants increase bleeding risk after endoscopic sphincterotomy: a retrospective study.Masuda S, Koizumi K, Nishino T, Tazawa T, Kimura K, Tasaki J, Ichita C, Sasaki A, Kako M, Uojima H, Sugitani A. BMC Gastroenterol. 2021 Oct 24;21(1):401. doi: 10.1186/s12876-021-01980-6.PMID: 34689751 Free PMC article.

58. Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver-related complications.Miyaaki H, Hiraoka A, Haraguchi M, Uojima H, Kawaratani H, Hiramatsu A, Hanai T, Hiasa Y, Yoshiji H, Okita K, Nakao K, Koike K.Hepatol Res. 2022 Apr;52(4):364-370. doi: 10.1111/hepr.13731. Epub 2021 Nov 19.PMID: 34755420

59. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis.Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S.Hepatol Res. 2022 Mar;52(3):269-280. doi: 10.1111/hepr.13732. Epub 2021 Nov 30.PMID: 34761470

60. Ultrasonography in the diagnosis of complications in patients with portal hypertension.Hidaka H, Uojima H.J Med Ultrason (2001). 2022 Jul;49(3):347-358. doi: 10.1007/s10396-021-01158-3. Epub 2021.PMID: 34787743 Review.

61. The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency.Shao X, Uojima H, Arai T, Ogawa Y, Setsu T, Atsukawa M, Furuichi Y, Arase Y, Horio K, Hidaka H, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Nakajima A, Terai S, Tanaka Y, Koizumi W.Dig Dis. 2022;40(5):625-634. doi: 10.1159/000521062. Epub 2021 Nov 22.PMID: 34808618 Free PMC article.Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group.Hepatol Res. 2022 Mar;52(3):235-246. doi:10.1111/hepr.13739. Epub 2021 Dec 17.PMID: 34861090

63. Splenectomy for Torsion of a Wandering Spleen in a Patient with Myeloproliferative Disease.Imawari K, Uojima H, Hayama K, Toshimitsu F, Sanoyama I, Iwasaki S, Wada N, Kubota K, Hidaka H, Nakazawa T, Shibuya A, Suzuki T, Kumamoto Y, Saegusa M.Intern Med. 2022 Jul 15;61(14):2143-2148. doi: 10.2169/internalmedicine.8391-21. Epub 2021 Dec 11.PMID: 34897151 Free PMC article.

64. Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.Furuichi Y, Takeuchi H, Uojima H, Atsukawa M, Arai T, Arase Y, Kako M, Hidaka H, Itoi T.J Hepatobiliary Pancreat Sci. 2022 Apr;29(4):439-448. doi: 10.1002/jhbp.1099. Epub 2022 Jan 8.PMID: 34953107

65. Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S.JGH Open. 2021 Dec 17;6(1):29-35. doi: 10.1002/jgh3.12691. eCollection 2022 Jan.PMID: 35071785 Free PMC article.

66. Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients.Ogushi K, Chuma M, Numata K, Nozaki A, Moriya S, Uojima H, Kondo M, Morimoto M, Maeda S.Eur J Gastroenterol Hepatol. 2022 Jul 1;34(7):774-781. doi: 10.1097/MEG.0000000000002346. Epub 2022 Jan 31.PMID: 35102114

67. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C.Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, Toyoda H, Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, Ikegami T, Abe H, Matsuura K, Tanaka Y, Tsubota A.Hepatol Commun. 2022 Aug;6(8):1855-1869. doi: 10.1002/hep4.1941. Epub 2022 Mar 28.PMID: 35344290 Free PMC article.

68. Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature.Masuda S, Tsukiyama T, Minagawa Y, Koizumi K, Kako M, Kinbara T, Haruki U.World J Clin Cases. 2022 Mar 16;10(8):2591-2603. doi: 10.12998/wjcc.v10.i8.2591.PMID: 35434047 Free PMC article.

69. A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M.BMC Cancer. 2022 May 7;22(1):517. doi: 10.1186/s12885-022-09625-x.PMID: 35525913

70. Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.Toyoda H, Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, Atsukawa M, Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, Tanaka J.J Infect Chemother. 2022 Sep;28(9):1231-1234. doi: 10.1016/j.jiac.2022.04.024. Epub 2022 May 6.PMID: 35534339

71. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment.Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S.Curr Oncol. 2022 May 4;29(5):3259-3271. doi: 10.3390/curroncol29050266.PMID: 35621656 Free PMC article.

72. Antibiotic Administration within Two Days after Successful Endoscopic Retrograde Cholangiopancreatography Is Sufficient for Mild and Moderate Acute Cholangitis.Masuda S, Koizumi K, Makazu M, Uojima H, Kubota J, Kimura K, Nishino T, Sumida C, Ichita C, Sasaki A, Shionoya K.J Clin Med. 2022 May 10;11(10):2697. doi: 10.3390/jcm11102697.PMID: 35628824 Free PMC article.

73. International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.Shiha G, Soliman R, Mikhail NNH, Carrat F, Azzi J, Nathalie GC, Toyoda H, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Atsukawa M, Abe H, Matsuura K, Mikami S, Watanabe T, Tsuji K, Ishikawa T, Suri V, Osinusi A, Ni L, Zou J, Sarin SK, Kumar M, Jalal PK, Hashim MA, Hassan M, Lopez SA, Bañares R, Ahumada AM, Mousa NH, Eslam M, Waked I.J Viral Hepat. 2022 Sep;29(9):807-816. doi: 10.1111/jvh.13717. Epub 2022 Jun 24.PMID: 35657138 Free article.

74. Evaluation of Skeletal Muscle Mass in Patients with Chronic Liver Disease Shows Different Results Based on Bioelectric Impedance Analysis and Computed Tomography.Kikuchi N, Uojima H, Hidaka H, Iwasaki S, Wada N, Kubota K, Nakazawa T, Shibuya A, KakoM, Take A, Sakaguchi Y, Sato T, Kusano C.Ann Nutr Metab.2022;78(6):336-344. doi: 10.1159/000526563. Epub 2022 Aug 18.PMID: 35981519 Free article.

75. The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma.Kawamura A, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Take A, Sakaguchi Y, Numata K, Kako M, Nozaki A, Azuma S, Horio K, Kusano C, Atsuda K.BMC Cancer. 2022 Aug 23;22(1):912. doi: 10.1186/s12885-022-10002-x.PMID: 35999529 Free PMC article.

76. A case of successful treatment with lenvatinib in primary hepatoid adenocarcinoma of the gallbladder that was difficult to distinguish from hepatocellular carcinoma.Iwasaki S, Hidaka H, Uojima H, Kubo H, Adachi K, Wada N, Kubota K, Nakazawa T, Shibuya A, Kusano C.Clin J Gastroenterol. 2022 Dec;15(6):1108-1114. doi: 10.1007/s12328-022-01686-6. Epub 2022 Aug 24. PMID: 36001231

77. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus.Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K.Hepatol Commun. 2022 Nov;6(11):3073-3082. doi: 10.1002/hep4.2069. Epub 2022 Aug 30.PMID: 36039537 Free PMC article.

78. B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis.Satoh T, Takiguchi H, Uojima H, Kubo M, Tanaka C, Yokoyama F, Wada N, Miyazaki K, Hidaka H, Kusano C, Kuwana M, Horie R.Ann Hematol. 2022 Nov;101(11):2433-2444. doi: 10.1007/s00277-022-04973-x. Epub 2022 Sep 13.PMID: 36098792

79. Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.Hayama K, Atsukawa M, Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, Toyoda H, Taniai N, Yoshida H, Tanaka Y, Iwakiri K; KTK49 Liver Study Group.Hepatol Res. 2023 Jan;53(1):51-60. doi: 10.1111/hepr.13840. Epub 2022 Oct 4.PMID: 36136893

80. Severe Generalized Epidemic Myalgia in an Adult due to Human Parechovirus Type 3: A Case Report.Masuda S, Koizumi K, Sato M, Uojima H, Kimura K, Nishino T, Ichita C, Sasaki A, Makazu M, Kobayashi M, Kubota J, Sumida C.Cureus. 2022 Oct 22;14(10):e30587. doi: 10.7759/cureus.30587. eCollection 2022 Oct.

81. Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study.Atsukawa M, Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, Ikegami T, Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K.Hepatol Int. 2023 Feb;17(1):139-149. doi: 10.1007/s12072-022-10456-y. Epub 2022 Dec 7.PMID: 36477691 Clinical Trial.

82. Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia.Satoh T, Uojima H, Wada N, Takiguchi H, Kaneko M, Nakamura M, Gonda N, Homma M,Hidaka H, Kusano C, Horie R.Platelets. 2023 Dec;34(1):2161498. doi:10.1080/09537104.2022.2161498.PMID: 36597279 Free article.

83. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S.Oncologist. 2023 Jul 5;28(7):e526-e533. doi: 10.1093/oncolo/oyad090.PMID: 37023703 Free PMC article.

84. Comprehensive review on endoscopic ultrasound-guided tissue acquisition techniques for solid pancreatic tumor.Masuda S, Koizumi K, Shionoya K, Jinushi R, Makazu M, Nishino T, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Haruki U.World J Gastroenterol. 2023 Mar 28;29(12):1863-1874. doi: 10.3748/wjg.v29.i12.1863.PMID: 37032729 Free PMC article. Review.

85. Comprehensive review on small common bile duct stones.Masuda S, Koizumi K, Shionoya K, Jinushi R, Makazu M, Nishino T, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Haruki U.World J Gastroenterol. 2023 Apr 7;29(13):1955-1968. doi: 10.3748/wjg.v29.i13.1955.PMID: 37155530 Free PMC article. Review.

86. A case of unsuccessful obliteration of percutaneous transhepatic gastric varices using the IMPEDE embolization plug.Masuda S, Tsukiyama T, Makazu M, Jinushi R, Koizumi K, Nishino T, Shionoya K, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Uojima H.Clin Case Rep. 2023 May 9;11(5):e07323. doi: 10.1002/ccr3.7323. eCollection 2023 May.

87. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH.Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16.PMID: 37184202

88. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.Wong YJ, Tran S, Huang CF, Hsu YC, Preda C, Toyoda H, Liu J, Jun DW, Landis C, Huang DQ, Gila A, Negoita L, Yasuda S, Tseng CH, Tsai PC, Uojima H, Nozaki A, Chuma M, Atsukawa M, Ishigami M, Itokawa N, Iio E, Lam CP, Watanabe T, Asai A, Yokohama K, Abe H, Enomoto M, Kawada N, Tamori A, Lee DH, Jun MJ, Do S, Vo DKH, Liu L, Li J, Ji F, Wang W, Li Y, Wang X, Guo F, Xu Q, Jing L, Ye Q, Pan H, Zhang J, Wen X, Wang Q, Ren H, Cai D, Shang J, Liu J, Lu C, Zang W, Li J, Niu J, Zhang M, Wu C, Huang R, Maeda M, Nakanishi A, Yeh ML, Chuang WL, Huang JF, Dai C, Ishikawa T, Takaguchi K, Senoh T, Trinh HN, Takahashi H, Eguchi Y, Quek SXZ, Haga H, Ogawa E, Wong G, Buti M, Fukunishi S, Ueno Y, Yuen MF, Tanaka Y, Lim SG, Cheung R, Yu ML, Nguyen MH.Hepatol Int. 2023 Oct;17(5):1150-1161. doi: 10.1007/s12072-023-10547-4. Epub 2023 Jun 5.PMID: 37273170

89. Impact of liver fibrosis on the relative abundance of a urease-positive Streptococcus salivarius group from saliva in patients with chronic liver disease.Také A, Uojima H, Sakaguchi Y, Gotoh K, Satoh T, Hidaka H, Horio K, Mizokami M, Hayashi S, Kusano C.Hepatol Res. 2023 Oct;53(10):998-1007. doi: 10.1111/hepr.13930. Epub 2023 Jun 19.PMID: 37279155

90. Endoscopic Papillary Balloon Dilation Can Be Safely Performed in Patients on Dual Antiplatelet Therapy: A Pilot Study.Masuda S, Jinushi R, Koizumi K, Makazu M, Nishino T, Shionoya K, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Uojima H, Sugitani A.J Gastrointestin Liver Dis. 2023 Jun 22;32(2):216-221. doi: 10.15403/jgld-4764.PMID: 37345612 Free article.

91. Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy.Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A, Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C.Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):865-873.doi:10.1097/MEG.0000000000002581. Epub 2023 Jun 6.PMID: 37395239

92. Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.Toyoda H, Kanneganti M, Melendez-Torres J, Parikh ND, Jalal PK, Piñero F, Mendizabal M, Ridruejo E, Cheinquer H, Casadei-Gardini A, Weinmann A, Peck-Radosavljevic M, Dufour JF, Radu P, Shiha G, Soliman R, Sarin SK, Kumar M, Wang JH, Tangkijvanich P, Sukeepaisarnjaroen W, Atsukawa M, Uojima H, Nozaki A, Nakamuta M, Takaguchi K, Hiraoka A, Abe H, Matsuura K, Watanabe T, Shimada N, Tsuji K, Ishikawa T, Mikami S, Itobayashi E, Singal AG, Johnson PJ.Clin Gastroenterol Hepatol. 2024 Jan;22(1):72-80.e4. doi: 10.1016/j.cgh.2023.06.026. Epub 2023 Jul 11.PMID: 37442316 Free article.

93. Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study.Chau A, Yeh ML, Tsai PC, Huang DQ, Kim SE, Trinh H, Yoon EL, Oh H, Jeong JY, Ahn SB, An J, Tseng CH, Hsu YC, Jeong SW, Cho YK, Shim JJ, Kim HS, Ito T, Marciano S, Kawashima K, Suzuki T, Watanabe T, Nozaki A, Ishikawa T, Inoue K, Eguchi Y, Uojima H, Abe H, Takahashi H, Chuma M, Ishigami M, Hoang JK, Maeda M, Huang CF, Gadano A, Dai CY, Huang JF, Tanaka Y, Chuang WL, Lim SG, Cheung R, Yu ML, Jun DW, Nguyen MH.Clin Gastroenterol Hepatol. 2024 Mar;22(3):572-580.e5. doi: 10.1016/j.cgh.2023.09.002. Epub 2023 Sep 19.PMID: 37734582

94. Metabolic Dysfunction-Associated Fatty Liver Disease on Distinct Microbial Communities at the Bacterial Phylum Level.Uojima H, Sakaguchi Y, Gotoh K, Satoh T, Hidaka H, Take A, Horio K, Hayashi S, Kusano C.Dig Dis. 2024;42(1):61-69. doi: 10.1159/000534284. Epub 2023 Sep 28.PMID: 37769624 Free PMC article.

95. New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.Uojima H, Nakabayashi K, Yamasaki K, Sugiyama M, Ishii N, Shirabe K, Kyoutou T, Ueda K, Takahama Y, Tamaki N, Kurosaki M, Hidaka H, Kusano C, Amano K, Kawaguchi T, Taketomi A, Joshita S, Umemura T, Murakawa M, Asahina Y, Suzuki T, Matsuura K, Nishimura T, Iijima H, Sakamoto K, Ito K, Nishina S, Hino K, Toyoda H, Yatsuhashi H, Kage M, Mizokami M.J Gastroenterol. 2023 Dec;58(12):1252-1260. doi: 10.1007/s00535-023-02043-1. Epub 2023 Oct 8.PMID: 37812281

96. Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Huang JF, Chuang WL, Yeh ML, Dai CY, Huang CF, Nguyen MH, Yu ML.Kaohsiung J Med Sci. 2024 Feb;40(2):188-197. doi: 10.1002/kjm2.12771. Epub 2023 Oct 27.PMID: 37885338 Free article.

97. Exploration of predictors associated with bleeding in computed tomography-guided core needle splenic biopsy: A retrospective study.Masuda S, Tsukiyama T, Daigo R, Makazu M, Jinushi R, Koizumi K, Nishino T, Shionoya K, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Uojima H.Medicine (Baltimore). 2023 Nov 17;102(46):e34951. doi: 10.1097/MD.0000000000034951.PMID: 37986279 Free PMC article.

98. Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.Park JE, Nguyen VH, Tsai PC, Toyoda H, Leong J, Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, Roberts LR, Schwartz ME, Kumada T, Yu ML, Nguyen MH.Aliment Pharmacol Ther. 2024 Mar;59(6):742-751. doi: 10.1111/apt.17863. Epub 2024 Jan 3.PMID: 38173278

99. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.Huang DQ, Hoang JK, Kamal R, Tsai PC, Toyoda H, Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Won Jun D, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH.J Clin Oncol. 2024 Mar 1;42(7):790-799. doi: 10.1200/JCO.23.00757. Epub 2024 Jan 4.PMID: 38175991

100. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.Toyoda H, Tada T, Uojima H, Nozaki A, Chuma M, Takaguchi K, Hiraoka A, Abe H, Itobayashi E, Matsuura K, Atsukawa M, Watanabe T, Shimada N, Nakamuta M, Kojima M, Tsuji K, Mikami S, Ishikawa T, Yasuda S, Tsutsui A, Arai T, Kumada T, Tanaka Y, Tanaka J, Chayama K.J Gastroenterol Hepatol. 2024 May;39(5):949-954. doi:10.1111/jgh.16494. Epub 2024 Jan 30.PMID: 38291715

101. Effectiveness of antibiotic prophylaxis for acute esophageal variceal bleeding in patients with band ligation: A large observational study.Ichita C, Shimizu S, Goto T, Haruki U, Itoh N, Iwagami M, Sasaki A.World J Gastroenterol. 2024 Jan 21;30(3):238-251. doi: 10.3748/wjg.v30.i3.238.PMID: 38314133 Free PMC article.

102. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer.Yamanaka T, Araki K, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Ishii N, Tsukagoshi M, Watanabe A, Harimoto N, Masamune A, Uojima H, Mizokami M, Ito K, Shirabe K.Cancer Sci. 2024 Apr;115(4):1241-1249. doi: 10.1111/cas.16087. Epub 2024 Feb 6.PMID: 38321872 Free PMC article.

103. Association of short-course antimicrobial therapy and bacterial resistance in acute cholangitis: Retrospective cohort study.Masuda S, Jinushi R, Imamura Y, Kubota J, Kimura K, Shionoya K, Makazu M, Sato R, Kako M, Kobayashi M, Uojima H, Koizumi K.Endosc Int Open. 2024 Feb 28;12(2):E307-E316. doi: 10.1055/a-2230-8229. eCollection 2024 Feb.PMID: 38420157 Free PMC article.

104. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.Kobayashi S, Fukushima T, Ueno M, Chuma M, Numata K, Tsuruya K, Arase Y, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Uojima H, Hidaka H, Kusano C, Morimoto M, Maeda S.Liver Int. 2024 Jun;44(6):1343-1350. doi: 10.1111/liv.15825. Epub 2024 Mar 4. PMID: 38436529

105. Development and validation of a scoring system for in-hospital mortality following band ligation in esophageal variceal bleeding.Ichita C, Goto T, Okada Y, Uojima H, Iwagami M, Sasaki A, Shimizu S.Dig Endosc. 2024 Mar 11. doi: 10.1111/den.14773. Online ahead of print.PMID: 38462957

106. Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino I E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML.J Gastroenterol Hepatol. 2024 Jun;39(6):1190-1197. doi: 10.1111/jgh.16537. Epub 2024 Mar 13.PMID: 38480009

107. Antimicrobial therapy outcomes in acute cholangitis: Hilar multiple obstructions versus single hilar and common bile duct obstructions. Masuda S, Imamura Y, Jinushi R, Kubota J, Kimura K, Makazu M, Sato R, Kako M, Kobayashi M, Uojima H, Ichita C, Koizumi K.JGH Open. 2024 Mar 14;8(3):e13047. doi: 10.1002/jgh3.13047. eCollection 2024 Mar.PMID: 38486876 Free PMC article.

108. Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.Uojima H, Yamasaki K, Sugiyama M, Kage M, Ishii N, Shirabe K, Hidaka H, Kusano C, Murakawa M, Asahina Y, Nishimura T, Iijima H, Sakamoto K, Ito K, Amano K, Kawaguchi T, Tamaki N, Kurosaki M, Suzuki T, Matsuura K, Taketomi A, Joshita S, Umemura T, Nishina S, Hino K, Toyoda H, Yatsuhashi H, Mizokami M.J Gastroenterol. 2024 Jul;59(7):598-608. doi: 10.1007/s00535-024-02100-3. Epub 2024 Apr 16.PMID: 38625546

109. Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.Itokawa N, Atsukawa M, Tsubota A, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Ogawa C, Hiraoka A, Okubo H, Uojima H, Chuma M, Nozaki A, Kato K, Mikami S, Tani J, Morishita A, Tada T, Asano T, Senoh T, Oikawa T, Okubo T, Kumada T, Iwakiri K.Hepatol Res. 2024 Apr 29. doi: 10.1111/hepr.14052. Online ahead of print.PMID: 38685853

110. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.Atsukawa M, Tsubota A, Kondo C, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Morishita A, Tani J, Okubo H, Hiraoka A, Nozaki A, Chuma M, Kawata K, Uojima H, Ogawa C, Asano T, Mikami S, Kato K, Matsuura K, Ikegami T, Ishikawa T, Tsuji K, Tada T, Tsutsui A, Senoh T, Kitamura M, Okubo T, Arai T, Kohjima M, Morita K, Akahane T, Nishikawa H, Iwasa M, Tanaka Y, Iwakiri K.J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109-8. Online ahead of print.PMID: 38727822

111. Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.Nakamura T, Masuda A, Kako M, Enomoto H, Kaibori M, Fujita Y, Tanizawa K, Ioji T, Fujimori Y, Fukami K, Hazama T, Iwamoto H, Kako Y, Kobayashi K, Koga H, Nagafuji K, Ohtake T, Suzuki H, Takashima T, Tsukiyama T, Uojima H, Yamahara K, Yamakado K, Yamamoto H, Yoh K, Yoshihara S, Kawamoto A, Nishiguchi S, Kobayashi S, Torimura T, Kawaguchi T.Regen Ther. 2024 May 4;27:455-463. doi: 10.1016/j.reth.2024.04.018. eCollection 2024 Dec.PMID: 38737403 Free PMC article.

112. Efficacy of Short-Course Antibiotic Therapy for Acute Cholangitis With Positive Blood Cultures: A Retrospective Study.Masuda S, Imamura Y, Ichita C, Jinushi R, Kubota J, Kimura K, Makazu M, Sato R, Uojima H, Koizumi K.Cureus. 2024 Apr 24;16(4):e58883. doi: 10.7759/cureus.58883. eCollection 2024 Apr.PMID: 38800172 Free PMC article.

113. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world.Kudaravalli S, Huang DQ, Yeh ML, Trinh L, Tsai PC, Hsu YC, Kam LY, Nguyen VH, Ogawa E, Lee DH, Ito T, Watanabe T, Enomoto M, Preda CM, Ko MKL, Wan-Hin Hui R, Atsukawa M, Suzuki T, Marciano S, Barreira A, Do S, Uojima H, Takahashi H, Quek SXZ, Toe Wai Khine HH, Ishigami M, Itokawa N, Go MS, Kozuka R, Marin RI, Sandra I, Li J, Zhang JQ, Wong C, Yoshimaru Y, Vo DKH, Tseng CH, Lee CJ, Inoue K, Maeda M, Hoang JK, Chau A, Chuang WL, Dai CY, Huang JF, Huang CF, Buti M, Tanaka Y, Gadano AC, Yuen MF, Cheung R, Lim SG, Trinh HN, Toyoda H, Yu ML, Nguyen MH.J Hepatol. 2024 Jul;81(1):33-41. doi: 10.1016/j.jhep.2024.02.033. Epub 2024 May 1.PMID: 38906621

114. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A multicenter study.Zhang Y, Numata K, Imajo K, Uojima H, Funaoka A, Komiyama S, Ogushi K, Chuma M, Irie K, Kokubu S, Yoneda M, Kobayashi T, Hidaka H, Fukushima T, Kobayashi S, Morimoto M, Kagawa T, Hattori N, Watanabe T, Iwase S, Maeda S.Hepatol Res. 2024 Jul 2. doi: 10.1111/hepr.14089. Online ahead of print.PMID: 38953838

115. Complete Match of Streptococcus salivarius from Oral Saliva and Stool in a Patient with Hepatic Encephalopathy.Nomura N, Také A, Uojima H, Sakaguchi Y, Gotoh K, Satoh T, Hidaka H, Horio K, Mizokami M, Hayashi S, Kusano C.Intern Med. 2024 Jul 4. doi: 10.2169/internalmedicine.3989-24. Online ahead of print.PMID: 38960683 Free article.

116. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.Chuma M, Uojima H, Toyoda H, Hiraoka A, Arase Y, Atsukawa M, Itokawa N, Okubo T, Tada T, Numata K, Morimoto M, Sugimori M, Nozaki A, Iwasaki S, Yasuda S, Koshiyama Y, Mishima Y, Tsuruya K, Tokoro C, Miura Y, Hidaka H, Kumada T, Kusano C, Kagawa T, Maeda S.Hepatol Int. 2024 Jul 4. doi: 10.1007/s12072-024-10680-8. Online ahead of print.PMID: 38963640

117. Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study.Naoki K, Igawa S, Uojima H, Tsumura H, Sengoku N, Karayama M, Shimomura A, Ohtake T, Shio Y, Hosokawa A, Komatsu Y, Kumagai Y.Cancer. 2024 Jul 10. doi: 10.1002/cncr.35447. Online ahead of print.PMID: 38985885

118. Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study.Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, Kakizaki S, Kagawa T, Miuma S, Suzuki T, Sugi K, Suyama K, Beppu T, Toyoda H, Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y.Hepatol Res. 2024 Jul 11. doi: 10.1111/hepr.14092. Online ahead of print.PMID: 38990762

119. Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, Toyoda H, Jun DW, Li L, Uojima H, Nozaki A, Chuma M, Tseng CH, Hsu YC, Ishigami M, Honda T, Atsukawa M, Haga H, Enomoto M, Trinh H, Preda CM, Vutien P, Landis C, Lee DH, Watanabe T, Takahashi H, Abe H, Asai A, Eguchi Y, Li J, Wang X, Li J, Liu J, Liang J, Lam CP, Huang R, Ye Q, Pan H, Zhang J, Cai D, Wang Q, Huang DQ, Wong G, Wong VW, Li J, Do S, Furusyo N, Nakamuta M, Nomura H, Kajiwara E, Yoon EL, Ahn SB, Azuma K, Dohmen K, An J, Song DS, Cho HC, Kawano A, Koyanagi T, Ooho A, Satoh T, Takahashi K, Yeh ML, Tsai PC, Yasuda S, Zhao Y, Liu Y, Okubo T, Itokawa N, Jun MJ, Ishikawa T, Takaguchi K, Senoh T, Zhang M, Zhao C, Alecu RI, Xuan Tay W, Devan P, Liu JK, Kozuka R, Vargas-Accarino E, Do AT, Maeda M, Chuang WL, Huang JF, Dai CY, Cheung R, Buti M, Niu J, Xie W, Ren H, Lim SG, Wu C, Yuen MF, Shang J, Zhu Q, Ueno Y, Tanaka Y, Hayashi J, Yu ML, Nguyen MH.J Clin Transl Hepatol. 2024 Jul 28;12(7):646-658. doi: 10.14218/JCTH.2024.00089. Epub 2024 Jun 17.PMID: 38993510 Free PMC article.

120. Uojima H＊, Kobayashi S, Hidaka H, Matsumoto S, Ohtake T, Kinbara T, Oka M, Yamanouchi Y, Kunieda T, Yamanoue H, Kanemaru T, Tsutsumi K, Fujikawa T, Sung Ji Hyun, Kako M. Virological response to daclatasvir and asunaprevir combination therapy for Chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study. Renal Replacement Therapy, 3: 7, 2017.
121. Tanaka Y, Masaki T, Uojima H＊, Ohtake T, Fujikawa T, Yamanouchi T, Wada N, Kubota K, Hidaka H, Nakazawa T, Shibuya A, Aoyama T, Sung H, Kako M, Kobayashi S, Takeuchi Y and Koizumi W.Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis. Renal Replacement Therapy2018 4:51. https://doi.org/10.1186/s41100-018-0193-4